Alpha-synuclein gene promoter (SNCA promoter)

The Alpha-synuclein gene promoter is the regulatory DNA sequence that controls the expression of the SNCA gene, which encodes the alpha-synuclein protein. This promoter is a primary therapeutic target because the overproduction of alpha-synuclein is a central driver in the pathogenesis of Parkinson's disease and other synucleinopathies (Mittal et al., 2017) [1]. Genetic variations within the promoter, such as the Rep1 microsatellite, have been clinically linked to an increased risk and earlier onset of neurodegenerative disorders (Pihlstrøm et al., 2018) [3]. Pharmacological modulation of this target often involves the use of beta-2 adrenergic receptor agonists, which have been shown to reduce SNCA transcription by altering histone acetylation patterns (specifically H3K27ac) at the promoter site (Mittal et al., 2017) [1]. Additionally, epigenetic strategies focusing on increasing DNA methylation at the SNCA promoter are being explored to silence gene expression in affected neurons (Desplats et al., 2011) [2]. Reducing alpha-synuclein levels at the source—transcription—is considered a promising approach to prevent the toxic aggregation of the protein into Lewy bodies. However, therapeutic interventions must carefully balance the reduction of toxic protein levels with the preservation of alpha-synuclein's physiological role in synaptic vesicle trafficking and neurotransmitter release (Theisler et al., 2021) [4].

Other names

SNCA promoterNACP promoterAlpha-synuclein regulatory regionSNCA 5' flanking regionSNCA Rep1

Downregulation of SNCA gene transcription through modulation of histone acetylation (specifically H3K27ac) or increasing DNA methylation at the promoter region to reduce protein expression levels.